Ankr Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI that virtualizes clinic front desk, medical assistant, and scribe functions for on-demand virtual clinics; YC-backed at $2.3M revenue with EHR integration generating $1M new revenue for average clinic.
About
Ankr Health is a San Francisco-based healthcare technology company using generative AI to virtualize clinic infrastructure — automating front desk operations, medical assistant workflows, and clinical documentation (AI scribe functions) that enable physicians to launch on-demand virtual and hybrid clinics without the full overhead of physical clinic staff. Founded in 2022 and backed by Y Combinator with $500,000 raised from MedTech Innovator, WorldQuant Ventures, and YC, Ankr Health generated $2.3 million in revenue in 2024 with a 15-person team, with integration across all major EHR systems (Epic, Cerner, athenahealth) and a reported $1 million in new annual revenue generated for average clinic customers.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.